Preventing end-stage renal disease: Flexible strategies to overcome obstacles

Current Opinion in Nephrology and Hypertension

Volumn 15, Issue 5, 2006, Pages 473-480

  Hirsch, Sheldon ^a,b  

^a MICHAEL REESE HOSPITAL   (United States)

^b Lakeside Nephrology   (United States)

Author keywords

Aldosterone receptor antagonists; Angiotensin 2 type 1 receptor blockers; Angiotensin converting enzyme inhibitors; Chronic kidney disease; End stage renal disease

Indexed keywords

HORMONE; LIPID; STEROL REGULATORY ELEMENT BINDING PROTEIN;

ADIPOCYTE; BODY MASS; CHRONIC DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; GLOMERULOPATHY; HEMODYNAMICS; HUMAN; INCIDENCE; KIDNEY AGENESIS; KIDNEY FAILURE; NEPHRECTOMY; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; WEIGHT REDUCTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIURESIS; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 33747339455     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mnh.0000242171.29329.1d     Document Type: Review

References (74)

1. Brenner B. The history and future of renoprotection. Kidney Int 2003; 64:1163-1168.
2. Brenner B, Zagrobelny J. Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors. Kidney Int 2003; 63 (Suppl 83):S77-S85.
3. Zandi-Nejad K, Brenner B. Strategies to retard the progression of chronic kidney disease. Med Clin North Am 2005; 89:489-509.
4. Hebert L, Wilmer W, Falkenhain M, et al. Renoprotection: one or many therapies? Kidney Int 2001; 59:1211-1226.
5. Ruggenenti P, Schieppate A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet 2001; 357:1601-1608.
6. Bakris G, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertensive and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36:646-661.
7. Campbell R, Ruggenenti P, Remuzzi G. Halting the progression of chronic nephropathy. J Am Soc Nephrol 2002; 13 (Suppl 3):S190-S195.
8. Remuzzi G, Ruggenenti P, Perico N. Chronic Renal Diseases: renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med 2002;136:604-615.
9. Remuzzi G, Perico N, Macia M, Ruggenenti P. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int 2005; 68 (Suppl 99):S57-S65.
10. Codreanu I, Perico N, Remuzzi G. Dual blockade of the renin-angiotensin system: the ultimate treatment for renal protection? J Am Soc Nephrol 2005;16 (Suppl 1):S34-S38.
11. Lewis E, Hunsicker L, Bain R, Rohde R. The effect of angiotensin- converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329:1456-1462.
12. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. Lancet 1997; 349:1857-1863.
13. Hou F, Zhang X, Zhang G, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006; 354:131-140.
14. Brenner B, Cooper M, De Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
15. Lewis E, Hunsicker L, Clarke W, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
16. Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-11 receptor blocker and angiotensin-converting-enzyme inhibitor in nondiabetic renal disease (COOPERATE): a randomized controlled trial. Lancet 2003; 361:117-124.
17. Jones C, Krolewski A, Rogus J, et al. Epidemic of end-stage renal disease in people with diabetes in the United States population: do we know the cause? Kidney Int 2005; 67:1684-1691.
18. US Renal Data System, Excerpts from the USRDS 2005 Annual Data Report. Am J Kidney Dis 2006; 47(Suppl 1):S1-S286.
19. Gaziano J. Global burden of cardiovascular disease. In: Pipes D, Libby P, Bonow R, Braunwald E, editors. Braunwald's heart disease, 7th ed Philadelphia, PA: Elsevier Saunders Co; 2005. pp. 1-6. chap 1.
20. Jemal A, Ward E, Thun M. Cancer statistics. In: DeVita V, Hellman S, Rosenberg S, editors. Cancer: principles and practice of oncology, 7th ed Philadelphia, PA: Lippincott Williams and Wilkins; 2005. pp. 226-240. chap 11.
21. Navis G, Kramer A, de Jong P. High-dose ACE inhibition: can it improve renoprotection? Am J Kidney Dis 2002; 40:664-666.
22. Schmieder R, Klingbeil A, Fleischmann E, et al. Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J Am Soc Nephrol 2005; 16:3038-3045.
23. Aranda P, Segura J, Ruilope L, et al. Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies. Am J Kidney Dis 2005; 46:1074-1079.
24. Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 2005; 67:799-812.
25. Epstein M. Aldosterone receptor blockade and the role of eplererone: evolving perspectives. Nephrol Dial Transplant 2003; 18:1984-1992.
26. Schjoedt K, Rossing K, Juhl T, et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 2005; 68:2829-2836.
27. Rossing K, Schjoedt K, Smidt U, et al. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy. Diabetes Care 2005; 28:2106-2112.
28. Klahr S, Levey A, Beck G, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 1994; 330:877-884.
29. Bakris G, Weir M, DeQuattro V, McMahon F. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998; 54:1283-1289.
30. Agarwal R, Acharya M, Tian J, et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005; 68:2823-2828.
31. Fisher N, Hollenber N. Renin inhibition: what are the therapeutic opportunities? J Am Soc Nephrol 2005; 16:592-599.
32. Weber M. Vasopeptidase inhibitors. Lancet 2001; 358:1525-1532.
33. Coresh J, Muntner P. Diabetic end-stage renal disease: has the epidemic reached a plateau? Neph-SAP 2005; 4:287-292.
34. Bloomgarden Z. Angiotensin ll receptor blockers and nephropathy trials. Diabetes Care 2001; 24:1834-1838.
35. Craig KJ, Donavon K, Munnery M, et al. Identification and management of diabetic nephropathy in the diabetes clinic. Diabetes Care 2003; 26:1806-1811.
36. Nau D, Garber M, Herman W. The intensification of drug therapy for diabetes and its complications. Am J Manag Care 2004; 10:118-123.
37. Schaars C, Denig P, Kasje W, et al. Physician, organizational, and patient factors associated with suboptimal blood pressure management in type 2 diabetic patients in primary care. Diabetes Care 2004; 27:123-128.
38. Winkelmayer W, Fischer M, Schneeweiss S, et al. Underuse of ACE inhibitors and angiotensin 11 receptor blockers in elderly patients with diabetes. Am J Kidney Dis 2005; 46:1080-1087.
39. National Kidney Foundation Kidney early evaluation program 2005. Annual data report. Am J Kidney Dis 2005; 46 (Suppl 3):S58-S59.
40. Tonelli M, Gill J, Pandeya S, et al. Barriers to blood pressure control and angiotensin enzyme inhibitor use in Canadian patients with chronic renal insufficiency. Nephrol Dial Transplant 2002; 17:1426-1433.
41. Thananayooran S, Rose C, Hirsch D. Effectiveness of a multidisciplinary kidney disease clinic in achieving treatment guideline targets. Nephrol Dial Transplant 2005; 20:2385-2393.
42. Minutolo R, De Nicola L, Zamboli P, et al. Management of hypertension in patients with CKD: differences between primary and tertiary care settings. Am J Kidney Dis 2005; 46:18-25.
43. Bakris G, Weir M. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine. Arch Intern Med 2000; 160:685-693.
44. Palmer B. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what to do if the serum creatinine and/or potassium concentration rises. Nephrol Dial Transplant 2003; 18:1973-1975.
45. Palmer B. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004; 351:585-592.
46. Rodby R, Rohde R, Clarke W. The irbesartan type 2 diabetic nephropathy trial: study design and baseline patient characteristics. Nephrol Dial Transplant 2000; 15:487-497.
47. Bicket D. Using ACE inhibitors appropriately. Am Fam Physician 2002; 66:461-468.
48. National Kidney Foundation. K/DOQI: clinical practice guideline on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004; 43 (Suppl 1):S120-S141, S183-S222.
49. Ahmed A. Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine? J Am Geriatr Soc 2002; 50:1297-1300.
50. Garovic V, Kane G, Schwartz G. Renovascular hypertension: balancing the controversies in diagnosis and treatment. Cleve Clin J Med 2005; 72:1135-1146.
51. Palmer B. Renal dysfunction complicating the treatment of hypertension. N Engl J Med 2002; 347:1256-1261.
52. Brenner B, Dworkin L, Ichikawa I. Glomerular filtration. In: Brenner, Rector, editors. The kidney, 3rd ed. Philadelphia, PA: W.B. Saunders Company; 1986. pp. 127-130. chap 4.
53. Hricik D, Browning P, Kopelman R, et al. Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenoses or renal-artery stenosis in a solitary kidney. N Engl J Med 1983; 308:373-376.
54. Apperloo A, De Zeeuw D, De Jong P. A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 1997; 51:793-797.
55. Berlowitz D, Ash A, Hickey E, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998; 339:1957-1963.
56. Hyman D, Pavlik V. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 2001; 345:479-486.
57. Oliveria S, Lapuerta P, McCarthy B, et al. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med 2002; 162:413-420.
58. Hyman D, Pavlik V. Poor hypertension control: let's stop blaming the patients. Cleve Clin J Med 2002; 69:793-799.
59. AT The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157:2413-2446.
60. AT The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA, 2003; 289:2560-2572.
61. Vasavada N, Agarwal R. Role of excess volume in the pathophysiology of hypertension in chronic kidney disease. Kidney Int 2003; 64:1772-1779.
62. De Nicola L, Minutolo R, Bellizzi V, et al. Achievement of target blood pressure levels in chronic kidney disease: a salty question? Am J Kidney Dis 2004; 43:782-795.
63. Khosla U, Johnson R. Hypertension in the hemodialysis patient and the 'Lag Phenomenon': insights into pathophysiology and clinical management. Am J Kidney Dis 2004; 43:739-751.
64. Schwenger V, Ritz E. Audit of antihypertensive treatment in patients with renal failure. Nephrol Dial Transplant 1998; 13:3091-3095.
65. Packer M, Lee W, Medina N, et al. Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure. Ann Intern Med 1987; 106:346-354.
66. Knight E, Glynn R, McIntyre K, et al. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies on left ventricular dysfunction (SOLVD). Am Heart J 1999; 138:849-855.
67. Weinfeld M, Chertow G, Stevenson L. Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am Heart J 1999; 138:285-290
68. Townsend R, Holland B. Combination of converting enzyme inhibitor with diuretic for the treatment of hypertension. Arch Intern Med 1990; 150:1175-1183.
69. Dustan H, Tarazi R, Bravo E. Dependence of arterial pressure on intravascular volume in treated hypertensive patients. N Engl J Med 1972; 286:861-866.
70. Taler S, Textor S, Augustine J. Resistant hypertension. Hypertension 2002; 39:982-988.
71. Forman JP, Brenner BM. 'Hypertension' and 'microalbuminuria': the bell tolls for thee. Kidney Int 2006; 69:22-28.
72. NKF-DOQI clinical practice guidelines for peritoneal dialysis adequacy. New York, National Kidney Foundation, 1997, 17-22.
73. Tinetti M, Bogardus S, Agostini J. Potential pitfalls of disease-specific guidelines for patients with multiple conditions. N Engl J Med 2004; 351:2870-2874.
74. Grimshaw J. Effect of clinical guidelines on medical practice: a systemic review of rigorous evaluations. Lancet 1993; 342:1317-1322.